Introduction
Breast cancer growth can be estrogen-dependent or -independent. Estrogen-dependent breast cancer, that is breast cancer expressing functional estrogen receptors (ER) and requiring estrogen for growth, has a better prognosis than estrogen-independent, ER negative breast cancer (Knight et al., 1977; De Sombre et al., 1986; Clark and McGuire, 1988; McGuire et al., 1990) . This better prognosis is re¯ected in both a longer disease-free survival and overall survival and responsivity to endocrine therapies such as the antiestrogen tamoxifen.
It is well established that estrogen treatment of ER+ breast cancer cells results in increased growth and the increased expression of several growth factors such as transforming growth factor-a (TGF-a), as well as receptor tyrosine kinases such as the epidermal growth factor receptor (EGFR) (reviewed in Lippman and Dickson, 1989) . As a result, it has long been hypothesized that estrogen promotes cellular proliferation, in part, via the induction of speci®c growth factors and their cognate receptors thus setting up an autocrine loop. Upon progression to estrogen-independent growth, there is loss of ER expression and overexpression of certain growth factors/receptors, such as TGF-a and EGFR. Given this, it is also possible that signal transduction via receptor tyrosine kinases is a separate and alternate pathway and thus a mechanism for bypassing estrogenmediated eects. Upregulation of these pathways may, therefore, be an early event in progression to the ERphenotype. Many studies support this idea. Breast cancer cells overexpressing FGF-4, FGF-1, or heregulin become tumorigenic in nude mice in the absence of estrogen (McLeskey et al., 1993; Pietras et al., 1995) . Overexpression of EGFR or erbB-2 in breast cancer cells confers a growth advantage in estrogen-depleted media (Miller et al., 1994; Liu et al., 1995; Pietras et al., 1995) and can increase tumorigenesis in nude mice in the absence of estrogen.
Most of the tyrosine kinase receptors like EGFR, erbB-2 and ®broblast growth factor receptor (FGFR) transduce their signals via the GTP-binding protein Ras (reviewed in Ullrich and Schlessinger, 1990; Hunter and Karin, 1992; Fantl et al., 1993) . The pathways activated by Ras have been recently elucidated and many of the key intermediates have been identi®ed. One of the major pathways initiated by the EGFR ligands is the mitogen activated protein kinase (MAP kinase or MAPK) phosphorylation cascade (reviewed in Hill and Treisman, 1995) . Upon binding of ligand, the activated receptor interacts with and activates Ras, resulting in the subsequent activation of the Raf proto-oncogene. Raf-1, one of three Rafs (reviewed in Li et al., 1991; Magnuson et al., 1994) , is a serine/threonine kinase that can directly phosphorylate nuclear factors like p53 (Jamal and Zi, 1995) . It also activates MAP kinase kinase (MAPKK or MEK), a dual speci®city kinase that can phosphorylate both serine/threonine and tyrosine residues. MEK then phosphorylates MAPK on threonine and tyrosine, and the activated MAPK which is a serine/threonine kinase is able to phosphorylate several nuclear transcription factors inluding Myc, Elk and Rsk (Siegfried and Zi, 1990; Kolch et al., 1991; Alexandropoulos et al., 1992; Blenis, 1993; Thomas, 1992; Crews et al., 1992) . It is now known that not only can the activated Ras oncogene cause cellular transformation (Barbacid, 1987; Trahey et al., 1987) , but that activated v-Raf or a constitutively activated MAPKK can also result in transformation (Heidecker et al., 1990; Cleveland et al., 1994; Samuels et al., 1993; Mansour et al., 1994) .
We were interested in studying the role of Raf in human breast cancer for several reasons. First, there are several studies indicating that oncogenic Ras transfected into ER+ MCF-7 cells renders them estrogenindependent. Dickson et al. reported that oncogenic Ras in MCF-7s conferred estrogen-independent growth in vitro but not in vivo, and Sukumar et al. obtained similar results Sukumar et al., 1988) . In studies by Kasid et al. and Sommers et al., stable transfection of Ras into MCF-7 human breast cancer cells rendered them estrogen-independent in anchorage-dependent or -independent growth and resulted in limited growth in vivo, suggesting that constitutive activation of the Ras pathway could either substitute for or bypass entirely the requirement of estrogen for the growth of these cells (Kasid et al., 1985 Sommers et al., 1990) . While activating mutations of Ras are very rare in breast cancer, overexpression does occur in *70% of breast cancer cases Thor et al., 1986) . This overexpression may have signi®cant impact on the downstream eectors of Ras, such as Raf. A second reason to study Raf is that many other signaling systems such as protein kinase C (PKC) and protein kinase A (PKA) have been recently shown to activate or inactivate Raf respectively (Kolch et al., 1993; Wu et al., 1993; Vaillancourt et al., 1994) , suggesting that Raf may play a pivotal role in signal transduction by several dierent pathways known to be important in breast cancer.
In this study, we report that stable transfection of a constitutively active Raf kinase into MCF-7 cells results in estrogen-independent growth, but the cells remain responsive to estrogen. However, while the high Raf activity seems to allow for growth in the absence of estrogen this high activity is not compatible with growth in the presence of estrogen and continued growth in estrogen-containing medium results in down-regulated expression of the transfected Raf. In addition we found that high levels of Raf activity in these cells lead to apoptosis.
Results

Characterization of Raf transfectants for D-raf expression and kinase activity
To begin to study the role of Raf in breast cancer cells, ER+ MCF-7 cells were stably transfected with a constitutively active Raf construct or a construct lacking the Raf cDNA. This construct consists of two cytomegalovirus (CMV) promoters wherein the ®rst drives the expression of a hygromycin resistance gene and the second drives the expression of an amino terminal-truncated Raf (Figure 1 ). The deletion of the ®rst 305 nucleotides of Raf results in a constitutively active kinase (Heidecker et al., 1990; Samuels et al., 1993) . After selection of single cell clones and their expansion, 15 hygromycin resistant clones were analysed for expression of the transfected Raf (designated D-raf) by Western blotting. Of the 15, six were positive for expression of the *34 Kda truncated Raf. In addition, a pooled population of cells transfected with the vector alone (designated HCopool) was expanded and used as a control for endogenous Raf activity (Figure 2 ). An in vitro kinase assay was performed with Raf immunoprecipitated from the clones to determine if the transfected Raf exhibited high constitutive kinase activity as compared to the endogenous activity measured in the HCopool. High levels of kinase activity, several-fold over that seen for endogenous Raf in the control pool, were observed (Table 1) .
Six positive clones and the vector control pool were maintained in media containing phenol red and 10% fetal bovine serum (FBS) or were switched to growth in media without phenol red and 10% charcoal stripped serum (CCS) to examine the growth in the absence of estrogen (Figure 2) . At the point of this Figure 1 Expression vectors used for stable transfection of constitutively active Raf-1 into MCF-7 cells. The parental vector contains two transcription units each driven by the cytomegalovirus promoter. The ®rst unit consists of the gene for hygromycin B resistance, to allow for selection. For the vector control, there was no insert into the second unit. For the D-raf vector, a cDNA corresponding to amino acids 305 ± 648 was inserted into the second unit. This cDNA has in addition, a methionine with an upstream Kozak's consensus sequence and a glutamic acid upstream of the Raf sequence. The amino-terminal truncation of Raf results in a constitutively active kinase switch, the cells had been growing in FBS conditions for about 4 weeks. Over the ®rst 4 weeks in CCS, each of the clones appeared to be growing similar to cells in FBS, whereas the control vector-transfected cells grew poorly, as expected of MCF-7 cells in the absence of estrogen. After 8 weeks in CCS, three clones were growing very well, as were their counterparts in FBS media. The other three clones had slowed considerably. After another 6 weeks the growth patterns of the clones in CCS changed again; that is, the three clones that had been growing poorly now began to grow quite normally. Given thesē uctuations in growth exhibited by the individual clones, we were curious as to whether there had been alterations in the level of the transfected Raf expression over time in culture in FBS and CCS. We had previously seen a similar situation when EGFR or erbB-2 was stably overexpressed in MCF-7 cells, where the expression of the transfected EGFR or erbB-2 disappeared in the presence of estrogen (growth in FBS) but was stably high in the absence of estrogen (growth in CCS) (Miller et al., 1994; Liu et al., 1995) .
Loss of D-raf expression occurs in FBS-containing but not CCS-containing medium Figure 3a shows Western blot analysis of D-raf expression in the six clones at the various time points of growth in FBS or CCS described above. Each of the six clones exhibited varying degrees of decreased expression of D-raf after 8 weeks in FBS and increased expression when grown in CCS. Clone 35 exhibited an almost complete loss of expression after 8 weeks in FBS as well as in CCS. Initially, this clone grew very poorly 
raf 8c raf 27c b Figure 3 Expression of D-raf varies depending on culture conditions. (a) For each clone, the original lysate represents that which was made after the initial expansion of clones. FBS indicates continuous growth for *2 months in FBS, while CCS indicates continuous growth in CCS for *2 months and CCS LT (long term) for *3.5 months. At this time point, the three clones that had almost stopped growing in CCS at 2 months were now once again growing very well in CCS. For the two clones that had grown well from the start in CCS (clones 8 and 27), the¯oating cells were collected and replated, and these were also analysed (¯oat). Finally, clones 8 and 27 which had been growing well in CCS for *3 months were placed back in FBS and were again analysed after two passages (C?F2). Lysates (25 mg) were electrophoresed through 10% polyacrylamide gels, transferred, and probed with an anti-Raf polyclonal antibody prepared to the carboxy-terminal 12 amino acids of Raf-1 (Santa Cruz Biotech). (b) Clones growing long-term in CCS (designated with a`c' after the clone number) were returned to growth in FBS and analysed every two passages. c-lt refers to growth in CCS for *3.5 months (as in Figure 2 ), at which time the cells were placed back in FBS. c-lt2 represents *4 more passages in CCS and c-lt3 another four passages in CCS. f-x refers to the number of passages after switching to growth in FBS in the absence of estrogen, yet upon resumption of normal growth after 14 weeks in CCS, it showed a dramatic increase in D-raf expression. These data suggest that D-raf expression confers a growth advantage in the absence of estrogen and that the loss in expression observed in FBS was not a result of plasmid loss, since expression could be increased again by shifting growth conditions. To con®rm that plasmid loss was not occurring, Southern blot analysis of DNA obtained from cells immediately after thawing of the freeze downs of initial expanded clones (high levels of Draf expression) and from cells after long-term growth in FBS (signi®cantly decreased levels of D-raf) was performed. Even in clone 35, which has virtually no D-raf expression after months in FBS, the plasmid was still present in the same apparent copy number and with no evidence of rearrangement (data not shown).
Clones that had been growing long-term (14 weeks) in CCS and were stably expressing high D-raf levels (ccs-lt) were switched back to growth in FBS and analysed after every two passages for D-raf expression. Two representative clones are shown in Figure 3b . Both clone 8 and clone 27 exhibited a decrease in D-raf expression after just two passages in FBS. Further decreases occurred with continued passage in FBS, a total of *10-fold for clone 8c over 14 passages and *6-fold for clone 27c over six passages. A parallel culture maintained in CCS for another 6 weeks (ccs-lt2) does not exhibit decreased D-raf expression. These data, along with the FBS data of the other clones, suggest both that high levels of constitutive Raf activity are incompatible with growth in the presence of estrogen, and that the increased D-raf levels seen in CCS are reversible.
We were next interested in determining the rate of Draf loss in FBS. The clones were thawed again from the initial freeze-downs, and then monitored after every two passages of growth in FBS or CCS for D-raf expression. Shown in Figure 4 are three representative clones which exhibit dierent rates of loss of the transfected Raf (as determined by densitometric scanning of Western blots), with clone 35 having the fastest and most complete loss. Clone 14 shows a small, but reproducible decrease in D-raf, *1.5-fold. Clone 35 has a very rapid and signi®cant reduction, *6-fold by passage 8 and *14-fold by passage 20. Clone 27 has a more moderate rate but still signi®cant loss, *3-fold by passage 8 and *12-fold by passage 20. In all clones, the endogenous Raf protein expression remains relatively unchanged with continuous growth in FBS. It is of interest to note that clone 35, which in the original experiments grew poorly in CCS when ®rst switched into this media, also had a signi®cant decrease in D-raf by passage 4. Since the cells are passaged once a week (if growing in FBS), and since in the original experiments there was a lag time of about 4 weeks before switching to growth in CCS, it would appear that the reason for the initial poor growth in CCS was due to the fact that there had already been major reductions in D-raf levels. The cells resumed normal growth in CCS in temporal association with upregulated D-raf. In con®rmation of this, none of the clones exhibited signi®cant growth retardation in CCS when placed into CCS immediately upon thawing out. Furthermore, there was no decrease in D-raf expression when thawed cells were placed directly in CCS as there had been in the original set of experiments when they were grown in FBS before being switched to CCS ( Figure 3a ). As shown with clone 27, the levels actually increase *1.5-fold with increasing passages in CCS ( Figure 4 ). Endogenous Raf levels seem to decrease initially upon growth in CCS, but then gradually increase back to levels observed in cells growing in FBS. Thus these data con®rm that growth in FBS is incompatible with the expression of very high levels of Raf kinase activity, however these levels do allow for growth in the absence of estrogen.
Because the main reagent, but not the only one, that is removed from serum upon charcoal stripping is estrogen, it seemed likely that it was the estrogen in FBS-containing medium that was inducing the loss in D-raf expression. To see if this was the case, cells growing long-term in CCS were switched to growth in CCS supplemented with 10 79 M 17b-estradiol. Again, the cells were analysed by Western blotting followed by densitometric scanning every two passages to follow Draf expression, and while there are reductions in D-raf levels, they are not as rapid nor to the same extent as 69 -
-
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Figure 4 D-raf expression decreases with continuous passage in FBS-containing medium, but not in estrogen-depleted medium. Clones were analysed by Western blotting, as described above, every two passages starting with an original freeze-down to examine the FBS-induced loss of D-raf expression in more detail. Each clone was also cultured in CCS and analysed every two passages. Shown here are representative samples from three clones those that occur in FBS, a maximum of about twofold for raf35 at passage 4 ( Figure 5a ). Since the cells double less frequently in CCS+E2 than in FBS, it was possible that longer passage in estrogen would result in the same total decreases observed in FBS. Alternatively, it was also possible that estrogen is only partially responsible for the decreases. To determine which of these was the case, clones were grown continuously in CCS+E2 for several more passages. In addition, clones from early passages were grown either in FBS (where we expect to see loss of D-raf) or in FBS supplemented with the pure anti-estrogen ICI 182,780. If estrogen is the key factor in FBS resulting in down-regulation of D-raf, the speci®c blockade of estrogen action should abolish this eect. Shown in Figure 5b are the results from these experiments with a representative clone, Raf27. After 20 passages in CCS+E2, signi®cant loss of D-raf expression was observed. Furthermore, while eight passages in FBS resulted in D-raf down-regulation, growth in FBS+ICI for the same number of passages prevents this downregulation; in fact, D-raf levels increase as we observed for growth in CCS. Thus it appears that estrogen is responsible for the loss of D-raf.
D-raf message levels are also decreased in FBS
Northern analysis of the transfected Raf was performed to determine if the decreases observed in protein expression correlated with decreases in mRNA levels as well. RNA prepared from cells just after thawing (higher levels of D-raf protein expression) was compared to that from cells in long-term FBS (lower or no D-raf protein expression) for the transfected Raf mRNA and GAPDH. For each clone, the loss of D-raf protein expression correlates with a decrease in mRNA expresion ( Figure 6 ). In addition, RNA was prepared from clones growing in CCS for several passages. As with protein expression, these clones expresed higher levels of RNA for D-raf than their FBS early passage counterparts. In this ®gure, the endogenous Raf mRNA is also visible. These levels also seem to¯uctuate with the dierent growth conditions, although the overall levels, as well as the dierences, are much lower than for the transfected Raf. Furthermore, these¯uctuations are not re¯ected at the protein level (Figure 4 ), but this may be due to the lower level of sensitivity obtained with Western blotting.
High D-raf levels confer the capacity for anchoragedependent and -independent growth in the absence of estrogen
We next directly assessed the growth capabilities of these clones. The clones were thawed from early freezedowns so that they were expressing high levels of D-raf, and then they and the control pool were`quickstripped' to remove estrogen before being plated in CCS. In anchorage-dependent growth assays, HCopool, raf14, raf27, and raf35 have similar doubling times in FBS: 28, 27, 24, and 27 h, respectively ( Figure  7a ). Growth of HCopool in CCS, however plateaus at *day 4, and has a doubling time of 172 h over the course of the assay. The doubling times for raf14 (41 h), raf27 (47 h) and raf35 (78 h), while longer than those for growth in FBS, indicate the ability of the Draf to allow for growth in the absence of estrogen. It should be noted that the D-raf expression levels of raf35 in this experiment were greatly reduced compared to raf14 and raf27, corresponding to the increased doubling time displayed by raf35 in CCS. Clones were also assessed for growth in soft agar. As compared to the control cells, both raf14 and 27 formed colonies in the absence of estrogen (CCS): *300 colonies for raf14 and *500 colonies for raf27 compared to *50 for the control pool. Raf14 and 27 were still responsive to estrogen in that they formed more colonies in CCS+E 2 , and the antiestrogens tamoxifen and ICI had little or not eect on colony formation indicating the true absence of estrogen in the CCS (Figure 7b ). To further demonstrate the eects of D-raf expression on the ability to form colonies in soft agar in the absence of estrogen, we also assayed early passage and late passage raf27. Early passage raf27 again was able to form colonies in CCS, *300, whereas late passage raf27 (no D-raf expression) was no longer capable of colony formation in CCS, *50 colonies (Figure 7b ). Colony formation in FBS, however, was very similar for both passage numbers, *1000 for early passage and *1450 for late passage.
High D-raf induces apoptosis
A striking feature of these clones when growing in CCS is their morphology. As shown in Figure 8a and b, there appear to be two distinct cell morphologies when the cells are grown on plastic. The adherent cells grow in spheroid clusters rising from the cell monolayer (Figure 8a ). In addition, there are a large number of oating cells. Some of these¯oating cells represent the cell clusters detaching from the monolayer. The majority of¯oating cells, however, are rather large clear cells with the nucleus pushed over to one side (Figure 8b ). The clones growing in FBS also exhibit these general characteristics but to a lesser extent. As these morphologic characteristics were signi®cantly dierent from those of the control cells, we assayed the clones for their apoptotic index using a cell death ELISA assay which is designed to detect histone-bound DNA fragments in the cytoplasm. All of the clones growing in CCS exhibit high levels of apoptosis, compared with the control pool growing either in FBS or stripped of estrogen (Figure 8c ). These high levels of apoptosis correlate with D-raf expression since in FBS, raf35 with high levels of D-raf exhibits high levels of apoptosis but after long-term growth in FBS (no D-raf expression), these cells now resemble the control pool. When the¯oating cell populations were collected and assayed separately from the adherent cells, it was clear that these¯oating cells are signi®cantly enriched for apoptotic cells (Figure 8d ). Estrogen added to cells growing in CCS for 1 ± 2 weeks did not reverse the high levels of apoptosis observed; in fact, it appears that estrogen treatment for this length of time increases the apoptosis further. To con®rm that apoptosis was occurring in these cells, we assayed cytoplasmic extracts of cells for the presence of DNA laddering and we performed the Tunel Assay. Although, MCF-7 cells have not been previously demonstrated to display DNA laddering, the D-raf clones did display some DNA fragmentation in their cytoplasm, indicative of apoptosis (data not shown). In the Tunel Assay, both¯oating and adherent cells were collected and ®xed. Following incubation with terminal deoxytransferase and¯uorescein-labeled nucleotides, the cells were analysed by FACS. The positive control, human leukemia cells treated with campothecin to produce *30% apoptotic cells, show the expected second peak representative of apoptotic cells (Figure 9a) . The negative controls, HCopool, HCopool stripped of estrogen for 5 days, and HCopool adapted long-term to grow in CCS, all look very similar with a single peak of low¯uorescence (Figure 9b ). Since the D-raf transfectants undergo apoptosis at some constant rate, that is they are not treated with an apoptosis inducer, it did not seem likely that two distinct peaks would be seen. Rather, one would expect a single peak that is much broader or with a shoulder as compared to non-apoptotic cells. In fact, the peak obtained with raf14c is much broader and shifted to the right compared with HCopool cells adapted to grow in CCS (Figure 9c ). Since we had previously observed that the¯oating cell population was enriched for apoptotic cells, we also assayed these cells by Tunel. And, although the cell number was low resulting in more scatter, a second distinct peak of higher uorescence is evident (Figure 9d ).
Discussion
Given the importance of growth factor signaling systems in breast cancer, i.e. overexpression of EGFR or erbB-2 correlates with poor prognosis and overexpression of Ras in a high percentage of breast tumors, we were interested in examining a key intermediate in the propagation of these signaling pathways ± Raf-1 ± in breast cancer. One goal of this study was to determine the eects of constitutive Raf-1 kinase activity on the estrogen-dependent growth of breast cancer cells, speci®cally the ER+ MCF-7 human breast cancer cell line. We therefore constructed a constitutively active form of Raf by deleting the amino-terminal domain, thus leaving only the catalytic domain. This construct was stably transfected into ER+ MCF-7 cells and six, high expressing clones were selected for further analysis. During the course of this study, we observed that continued passage of the clones in the presence of estrogen (FBS and phenol red) resulted in a loss of expression of the transfected Raf. This loss is re¯ected at both protein (Figures 2 and 3) and message ( Figure 6 ) levels despite the continued presence of intact integrated plasmid sequences. We previously observed similar results when EGFR or c-erbB-2 was stably overexpressed in MCF-7 cells; that is growth of the transfected cells in estrogen-containing medium resulted in decreased expression of both protein and message but not loss of the plasmid (Miller et al., 1994; Liu et al., 1995) . While the parent vectors used in these transfections were similar (Figure 1) , when FGF-4 was expressed using these vectors, the same pattern of down-regulation in FBS and up-regulation in CCS was not observed (Miller et al., 1994) . Additionally, several other factors including collagenase IV and chloramphenicol acetyl transferase have been expressed in these vectors with no apparent problems, and there is no loss of CMV-driven drug-resistance when the selection agent is removed after expansion of drug-resistant colonies (Miller et al., 1994 ). It appears, therefore, that this pattern of downregulation occurs only when molecules that result in hyper-activation of growth signaling pathways other than the estrogen pathway are over-expressed. It would (c and d) Clones growing in CCS or in FBS (just after thawing so that D-raf levels are high) were analysed for levels of apoptosis using a cell death ELISA assay (Boehringer Mannheim). In this assay, cytoplasmic extracts are prepared from 150 000 cells. Apoptotic cell death is then measured using a ®rst antibody against histones and a second antibody against DNA. (c) HCopool growing in FBS, HCopool stripped of estrogen for 5 days and CCS clones (clone #c) growing in CCS or CCS+short-term E 2 (left), and raf35 growing in FBS at early passage with high D-raf levels and at late passage with no D-raf (right) were collected as total cell populations (¯oaters and adherents) and assayed. (d) CCS clones growing in CCS or CCS+short-term E 2 were collected as separate cell populations (¯oaters or adherents) and assayed seem, then, that the constitutive activation of these growth signaling pathways is incompatible with estrogen-induced growth of these cells and that the estrogen pathway dominates.
While growth of the transfectants in estrogencontaining medium was not compatible with high levels of constitutive Raf expression, these same high levels did confer a growth advantage to the cells in the absence of estrogen. All of the clones were able to grow in CCS medium but the control cells were not (Figure 7a ). Not only did growth in the absence of estrogen not cause a down-regulation of the D-raf, but the level of expression actually increased over time in culture over that seen in the FBS cells just after thawing (Figure 4) . These high levels of D-raf expression also permit colony formation in soft agar in the absence of estrogen (Figure 7b ). Previous work by others using EGFR, c-erbB-2 and the activated Ras oncogene has shown similar results (Miller et al., 1994; Liu et al., 1995; Pietras et al., 1995; Sukumar et al., 1988; Kasid et al., 1985 Kasid et al., , 1987 Sommers et al., 1990) . Both EGFR and c-erbB-2 overexpression allow for estrogen-independent growth in vitro, but only one clone which had a high level of activated c-erbB-2 was able to grow in vivo in the absence of estrogen (Liu et al., 1995) . Activated Ras can also confer a growth advantage to cells in the absence of estrogen both in anchorage-dependent and -independent growth assays. However, only two studies which used a Ras construct under the control of multiple long terminal repeats observed in vivo tumor formation in the absence of estrogen (Kasid et al., Sommers et al., 1990) . Our study, therefore, suggests that Raf is the downstream effector of Ras activity that results in estrogen-independence. It remains to be determined whether the estrogenindependence we have observed with Raf in vitro will also occur in vivo.
Since estrogen is the main component in serum that is removed upon charcoal stripping, we added estrogen back to the cells growing in CCS to determine that it was estrogen in FBS which caused the down-regulation of D-raf. While D-raf levels decreased when cells were passaged in CCS+E 2 (Figure 5) , it was not at the same rate as that which occurred in FBS. This is likely due to the fact that the cells grow somewhat slower in CCS+E 2 than in FBS and since the rate of D-raf loss may be a re¯ection of the doubling time of the cells, it may take more passages in CCS+E 2 to see the same degree of down-regulation. And in fact, when the cells were grown in FBS in the presence of a pure antiestrogen, no loss of D-raf occurred indicating that this is speci®c to estrogen and not to other substances removed by charcoal stripping. In addition, D-raf levels increased in FBS+ICI indicating a selective advantage to high Raf activity under these conditions.
An interesting feature of the transfectants was their morphology. In contrast to control cells which grow in a¯at monolayer and produce very few¯oating cells in FBS or CCS, the transfectants grow in CCS as spheroid clusters of cells rising out of the monolayer (Figure 8a ) and produce a large number of¯oating cells that consist of these spheroids and a population of cells that appears as large, clear cells with the nucleus pushed to one side (Figure 8b ). These¯oating cells exhibit very high levels of apoptosis. It is not so surprising that the¯oating cells themselves are apoptotic, rather it is the extent to which these cells produce large numbers of¯oating cells that diers. Certain cell systems, such as colon carcinoma cells, undergo apoptosis at a very low rate during normal culture of these cells (Heerdt et al., 1994; Bracey et al., 1995) . The apoptotic cells are¯oaters, and the number of¯oaters can be signi®cantly increased by agents that speci®cally induce apoptosis in these cell types.
However, there is some disagreement on whether MCF-7 cells can undergo apoptosis in vitro. It is well known that breast epithelial cells and breast cancer cells in vivo undergo apoptosis in response to estrogen withdrawal (Strange et al., 1992; Kyprianou et al., 1991) , but there has been an inability to measure this in cells growing in vitro, at least using the usual hallmarks of apoptosis: DNA laddering and morphology. With time-lapse microscopy providing more detailed visualization of cells, apoptosis has been observed in both MCF-7 and ZR-75-1 cells in vitro in response to estrogen withdrawal or treatment with the antiestrogen toremifene, although no DNA laddering was observed (Warri et al., 1993) . Some investigators have used nonrandom DNA cleavage into large (several to several hundred kb) fragments as a measure of apoptosis (Oberhammer et al., 1993) and found that by this criterium, estrogen-withdrawal resulted in cell detachment and DNA cleavage (Wilson et al., 1995) . The antiestrogen ICI 182,720 increased these parameters twofold, however the typical morphological alterations and DNA laddering of apoptosis were not observed. Using a recently described cell death ELISA assay, as we have used in our studies, investigators have been able to show that treatment of MCF-7 cells in vitro with VP-16, taxol, or tamoxifen does result in apoptosis (Sumantran et al., 1995; Wang and Phamg, 1995) .
Using this same assay, we show that the control pool in FBS exhibits virtually no apoptosis and that estrogen-withdrawal of these cells for up to 5 days does not increase the apoptotic index. The D-raf transfectants, however, have a high apoptotic index in CCS and FBS, and this appears to be dependent on high Draf levels since long-term passage in FBS which downregulated D-raf also abrogates the apoptosis ( Figure  8c ). In addition, we have been able to observe some DNA laddering in our system, presumably due to the fact that the apoptosis level in these cells is high and perhaps because we isolated DNA from cytoplasmic extracts. As further con®rmation, the Tunel assay was also performed. Apoptosis was observed in raf14c cells but not in control cells passaged either short-term or long-term in CCS (Figure 9 ).
The fact that high levels of Raf activity result in increased apoptosis in these cells provides a possible explanation for why the cells in FBS down-regulate Draf expression. When other growth-signaling pathways are operative in the cell, a selection against a pathway that leads to apoptosis occurs. On the other hand, cells cannot grow in the absence of estrogen without constitutive Raf signaling, and therefore they upregulate its expression and subsequently undergo apoptosis. However, a balance between growth stimulation and apoptosis must exist because all of the cells do not die. One possibility is that the threshold of Raf activity required for growth stimulation is lower than that required for apoptosis and not all cells express the same high levels. A second possibility is that all cells do express the same high levels and the induced apoptosis is likely to be a stochastic process in cells with uniformly high Raf activity.
Unlike the diculty in demonstrating apoptosis in ER+ breast cancer cell lines, the MDA-MB-468 human breast cancer cell line which is ER7 and overexpresses EGFR due to gene ampli®cation (Filmus et al., 1985) , readily undergoes apoptosis as demonstrated by DNA laddering in response to EGF treatment (Armstrong et al., 1994) . High doses of EGF cause growth inhibition and apoptosis in these cells suggesting that hyper-induction of growth factor signaling in these cells due to their EGFR overexpression may actually result in cell death as opposed to growth. It may be then, that our constitutive Raf transfectants undergo apoptosis via the same mechanisms and that the EGF induced apoptosis in MDA-MB-468s occurs through the Raf signaling pathway. On the other hand, MDA-MB-468 cells express mutant p53 while MCF-7 cells express wild-type p53. It has recently been shown that Raf is able to activate the transactivation capacity of p53 and in vitro phosphorylation studies have mapped the sites phosphorylated by Raf to the transactivation domain of p53 (Jamal and Zi, 1995) . It is therefore possible, that the Rafinduced apoptosis in our transfectants occurs via a p53-dependent mechanism ± a question that is currently under investigation.
A major question arising from these observations is how does constitutive activation of a growth pathway ultimately result in the opposite ± increased cell death. It is well established that several oncogenes, including Ras, Raf, Src and Abl, can cooperate to protect against or rescue cells from apoptosis (Lin et al., 1995; White et al., 1994; Cortez et al., 1995; . In the 32D.3 hemopoietic cell line, Raf has been shown to physically interact with the apoptosis inhibitor Bcl-2 and in this manner cooperates with Bcl-2 to inhibit apoptosis (Wang et al., 1994) . More recently however, it has been demonstrated that Taxol-induced apoptosis in MCF-7 cells is mediated by activation of Raf followed by phosphorylation of Bcl-2 (Blagosklonny et al., 1995 (Blagosklonny et al., , 1996 . There is increasing evidence that phosphorylation of Bcl-2 in such a manner inhibits its function thus leading to apoptosis (Haldar et al., 1995 (Haldar et al., , 1996 . Given these two opposite actions of Raf, the focus of ongoing investigation is thus to determine what the eect of constitutive Raf activity on the expression and function of known potentiators of apoptosis, and what the downstream eectors of this constitutive Raf activity are that are responsible for the increased apoptosis.
Materials and methods
Cell culture
MCF-7 human breast cancer cells were obtained from Marvin Rich (Michigan Cancer Foundation), and were maintained in Improved Minimal Essential Medium (IMEM, Gibco/BRL) with phenol red supplemented with 10% fetal bovine serum (FBS, Intergen Company) . For growth in the absence of estrogen, media was switched to IMEM supplemented with 10% charcoal stripped calf serum (CCS, Gibco/BRL). For certain experiments, cells were quick-stripped of estrogen by repeated rinsing of cells in IMEM and growth in IMEM+10% CCS (three times per day for 2 days). Hormone treatments, when performed, were with 17b-estradiol (Sigma) at 10 78 M or the pure antiestrogen, ICI 182,780 (obtained from Alan Wakeling, Zeneca Pharmaceuticals) at 10 77 M. Cells were plated in CoStar 75 cm 2 T-¯asks and grown in a forced air humidi®ed incubator in an atmosphere of 5% CO 2 and 378C.
Plasmid construction and transfection
The truncated Raf cDNA was obtained by PCR amplification of nucleotides 1040 ± 2075 (Bonner et al., 1986) using primers (5': CGGGATCCACCATGGAGCCGAAAACC-CCCGTGCCAGCAC; 3': ATCAACTGAAACGTGGA-CAGAAGTCCTAGGGC) with appended BamHI restriction sites to allow for insertion into the plasmid. Correct insertion and sequence was con®rmed by dideoxysequencing. As a result of sequence contained within the 5'-primer used for the PCR ampli®cation, the cDNA contains an inframe initiation codon with an upstream Kozak's consensus sequence followed by glutamic acid, and corresponds to a deletion of the ®rst 304 amino acids of Raf-1 resulting in constitutive kinase activity and high transforming activity in NIH3T3 cells (Heidecker et al., 1990; Samuels et al., 1993) . The predicted MW of the encoded protein is *35 kDa protein. The D-raf cDNA was inserted into the BamHI site of pCHC6Xho (Miller et al., 1994) , a pUC19-based plasmid with two transcription units, each driven by a CMV promoter. The ®rst unit contains the hygromycin resistance gene and the Raf cDNA composed the second unit. The vector with no cDNA insert was used for control transfection.
Transfections were performed using lipofectamine (Gibco/ BRL). Brie¯y, 20 ml of lipofectamine were incubated with 5 mg of plasmid DNA in serum-free IMEM for 30 min at room temperature (rt). After adding IMEM+5% FBS, the lipofectamine/DNA solution was incubated with MCF-7 cells (at *70% con¯uence in 10 cm tissue culture dishes) for 16 h at 378C. The cells were rinsed twice with serum-free IMEM and then re-fed with IMEM+10% FBS. After a 48 h recovery, the cells were split 1 : 6, allowed to plate for 24 h and then selected in FBS media containing 150 mg hygromycin B (Boehringer Mannheim). Individual colonies were selected using trypsin-soaked ®lter paper disks which were placed in 24-well plates in FBS media. Fifteen clones from each transfection were expanded and analysed for expression of the transfected Raf.
Gel electrophoresis and Western blotting
Cell lysates were prepared from 75 cm 2 T-¯asks in a similar manner as that described by Samuels et al. 1993 . Brie¯y, cells were rinsed in PBS and then lysed in the¯ask in a modi®ed Gold Lysis Buer (20 mM Tris, pH 7.9, 137 mM NaCl, 5 mM EDTA, 10% glycerol, 1% Triton X-100, 1 mM EGTA, 1 mM Pef-bloc A (Boehringer Mannheim, used instead of PMSF), 1 mM aprotinin, 1 mM leupeptin, 1 mM pepstatin A, 1 mM bacitracin, 1 mM Na 3 VO 4 , 1 mM sodium pyrophosphate, 10 mM sodium¯uoride) on ice, scraped into a microfuge tube and centrifuged at 12 000 g to pellet nuclear debris. Supernatants were analysed for protein content using the BCA protein assay kit (Pierce) and stored at 7208C.
For Raf Western blots, 25 mg of cellular lysate was electrophoresed through 10% SDS-polyacrylamide gels where the separating gel consisted of 10% acrylamide/0.1% bis-acrylamide and the stacking gel was 3% acrylamide/ 0.25% bis-acrylamide. 0.1% SDS was included in the gel and running buers. Rainbow molecular weight markers were from Amersham: myosin, MW 200 000; phosphorylase B, MW 97 400; bovine serum albumin, MW 69 000; ovalbumin, MR 46 000; carbonic anhydrase, MW 30 000; trypsin inhibitor, MW 21 500; and lysozyme, MW 14 300. Electrophoresed gels were transferred to 0.45 mm nitrocellulose (BioBlot NC, CoStar Corp.) for 2 h at 0.4 amps in Towbin's buer (20 mM Tris, 150 mM glycine, pH 8.3, 20% methanol, 0.1% SDS), and the blots were blocked in TBST (10 mM Tris, pH 7.5, 150 mM NaCl and 0.1% Tween-20) with 5% BSA and an additional 0.15% Tween-20 added for 60 min at rt. Blots were then incubated with an anti-Raf polyclonal antibody (made against the carboxy-terminal 12 amino acids from the human Raf-1 sequence, Santa Cruz) diluted to 1 mg/ ml in TBST plus 1% BSA overnight at 48C. After washing the blots 365 min with TBST, they were incubated with donkey anti-rabbit antiserum linked to horseradish peroxidase (Amersham) diluted 1 : 4000 in TBST/1% BSA for 60 min at rt. The blots were again washed in TBST, once for 20 min and then 365 min and the bound secondary antibody visualized using enhanced chemiluminescence (ECL, Amersham) according to manufacturer's instructions.
In vitro kinase assay
In vitro kinase assays for Raf activity were similar to that described by Samuels et al. (Miller et al., 1994) . Raf was ®rst immunoprecipitated from 100 mg cellular lysate using the same polyclonal anti-Raf antibody as for Westerns conjugated to agarose for 60 min at 48C. Immunoprecipitates were washed two times with lysis buer and then incubated with 30 ml reaction mix consisting of 25 mM N' -2 -hydroxyethylpiperazine -N' -2 -ethanesulfonic acid (HEPES, pH 7.4), 10 mM MgCl 2 , 1 mM MnCl 2 , 1 mM DTT, 1 mM ATP and 30 mCi [g-32 P]ATP. A synthetic peptide substrate for Raf-1 (Santa Cruz) was included in the reaction mix at 100 mM. After incubating for 30 min at 308C, reactions were transferred to spin-zyme ®lter units (Pierce) and centrifuged at 12 000 g for 30 s. Filters were washed twice with 75 mM Phosphoric Acid, and then transferred to scintillation vials and counted in a Beckman L57500 scintillation counter. Included in each assay was a no lysate control for background and lysate from the vector control pool cells as a control for endogenous Raf-1 activity.
RNA extraction and Northern analysis
RNA was extracted using a one-step acid-guanidinium method as described in (Chomczynski and Sacchi, 1987) . For Northern analysis, 10 mg of total RNA was electrophoresed through a 1% agarose/formaldehyde gel as described previously (Miller et al., 1994) . Following capillary transfer to nitrocellulose, the membrane was baked at 808C for 2 h. The blot was ®rst probed for GAPDH, used as a loading control. Construction and synthesis of GAPDH antisense riboprobe has been previously described (Miller et al., 1994) . Prehybridization, hybridization, and membrane stripping were carried out as previously described (Miller et al., 1994) . After probing for GAPDH, the blot was probed for expression of the transfected raf gene. Probe synthesis was by random hexamer priming of a BamHI 1029 bp fragment of the cDNA excised from pCHC6-raf as previously described (Miller et al., 1994) . The blot was prehybridized in 50% formamide, 56SSC, 56Denhardt's, 25 mM NaHPO4 for 4 h at 428C. Hybridization was carried out in prehybridization buer plus 10% (w/v) dextran sulfate overnight at 428C. The blot was washed twice at room temperature in 0.26SSC-0.1% SDS and twice in 0.16SSC-0.1% SDS at 658C for 20 min each. Blots were exposed at 7708C to Xray ®lm or quantitated with a Molecular Dynamics 445-SI PhosphorImager.
Growth assays
HCopool and D-raf clones were thawed from the original freeze-downs, with the exception of raf35 which had been passaged and was exhibiting reduced D-raf levels, and then quick-stripped to remove estrogens from the medium. For anchorage-dependent assays, cells were trypsinized and 10 000 cells were plated in CCS into triplicate wells of 24-well plates. After allowing the cells to plate for 24 h, an initial cell count was taken to give the Day 0 counts and various hormone treatments were added to the cells. Cell counts were performed every 2 days by aspirating the media and incubating the cells in PBS with 10 mM EDTA for 30 min at rt. Cells were counted in a Coulter automated cell counter (Coulter Electronics), the triplicates averaged, and values were plotted logarithmically. Doubling times were calculated from values obtained from the linear portion of the growth curve using the equation: where N 2 is the number of cells at t 2 and N 1 is the number of cells at t 1 . For anchorage-independent assays, 20 000 quick-stripped cells from original freeze-downs (i.e. early passage number), unless otherwise indicated, were plated in triplicate 35 mm dishes in CCS+0.36% agar+various hormones onto a bottom layer consisting of CCS+0.6% agar. Colonies greater than 60 mM in diameter were counted 9 days after plating using an Omnicon Image Analysis System.
Cell death ELISA assay
The kit was obtained from Boehringer Mannheim and the assay was performed according to the manufacturer's directions. Brie¯y,¯oating cells were collected and adherent cells were trypsinized and combined with thē oating cells. Cytoplasmic extracts were prepared from 150 000 cells. After coating ELISA plates with anti-histone antibody for 1 h at room temperature, extracts were incubated in coated wells for 1.5 h at rt, followed by washing and incubation with anti-DNA antibody linked to peroxidase for 1.5 h. After washing, wells were incubated with substrate for *15 min and absorbances were read on a Dynatech plate reader at 405 nm. All sample reactions were performed in duplicate and absorbance values were averaged.
Tunel assay
The ApoTag for FACS kit was obtained from Oncor and the assay was performed according to the kit directions. Control cells for the assay, a human leukemia cell line treated with campothecin for 24 h to induce *30% apoptosis, were obtained from Phoenix Flow Systems as already ®xed cells. Floating cells were collected and either combined with trypsinized adherent cells or analysed separately. Two million cells were ®xed for 15 min on ice in 1% paraformaldehyde. Following washes, cells were suspended in ice-cold 70% ethanol and stored at 7208C for less than 2 months prior to being analysed. Fixed cells were pelleted, washed, suspended in Equilibrium buer, and incubated with a reaction mix consisting of Tdt and uorescein-labeled nucleotides for 30 min at 378C. Cells were then washed, resuspended in Stop buer and analysed using a FACStar Plus laser system (Becton Dickinson).
